Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$299,843
-$35,801,974 QoQ
Shares Held
11,658
-99.4% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#180
of 290 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Lynx1 Capital Management LP holds $865,408,538 across 26 Biotechnology names. DNLI ranks #18 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GHRS |
GH Research PLC
|
13,263,288 | $356,517,181 | |
| 2 | CGEM |
Cullinan Therapeutics, Inc.
|
8,963,500 | $163,225,335 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
4,038,404 | $132,136,578 | |
| 4 | AGIO |
Agios Pharmaceuticals, Inc.
|
3,408,937 | $126,505,652 | |
| 5 | CCCC |
C4 Therapeutics, Inc.
|
7,326,691 | $34,215,646 | |
| 6 | KRRO |
Korro Bio, Inc.
|
1,538,296 | $20,274,741 | |
| 7 | TCRX |
TScan Therapeutics, Inc.
|
8,019,148 | $7,858,765 | |
| 8 | DTIL |
Precision Biosciences Inc
|
950,466 | $7,470,662 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $299,843 | 11,658 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $36,101,817 | 1,880,303 | Shares | Other | 2026-05-04 | |
| 2025-12-31 | $28,706,762 | 1,738,750 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $3,799,695 | 261,687 | Shares | Other | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||